AnHorn Medicines starts first human dosing of AH-008, an IV antibody candidate
A single-site Phase 1 in healthy volunteers will test AH-008's safety and pharmacokinetics, the first clinical readout for AnHorn's newest program.
Executive Summary
- AnHorn Medicines has begun recruiting for the first clinical trial of AH-008, an intravenously administered antibody candidate, testing it in healthy volunteers rather than patients.
- The design is built to characterize safety, tolerability and pharmacokinetics across ascending doses, the standard gateway data a sponsor needs before testing the drug in disease populations.
- This is AnHorn's second clinical-stage program on record, and the mechanism and target for AH-008 are not yet established in available data, so no competitive positioning can be drawn yet.
- The relevant catalyst is not the registration but the safety and PK data the dose-escalation cohorts generate as the trial completes.
The trial
The study, registered as NCT07697560, is a randomized, double-blind, placebo-controlled single ascending dose trial of AH-008 in adults aged 18 to 65. It plans to enroll 32 healthy subjects at one U.S. site, using sequential dose cohorts with a safety review committee overseeing dose escalation between cohorts. The trial started June 10, 2026, is listed as Recruiting, and carries a primary completion date of September 1, 2026. AnHorn+1AnHorn Medicines Registers Phase 1 Trial of AH-008 for Healthy SubjectsJul 13, 2026Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy SubjectsNCT07697560
What it measures
The registered primary endpoints are entirely safety and pharmacokinetic measures: incidence of clinically significant ECG abnormalities, clinical laboratory abnormalities, vital sign abnormalities, infusion site reactions, and treatment-emergent adverse events, each assessed from baseline through 48 hours after dosing. Alongside these, the trial will characterize AH-008's pharmacokinetic profile, including area under the concentration-time curve, maximum plasma concentration, time to maximum concentration, terminal half-life, and urinary excretion following a single intravenous dose. There is no efficacy endpoint in this design, consistent with a first-in-human safety study. NCT07697560Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy SubjectsNCT07697560
What the design can and cannot show
A 32-subject, single-site, healthy-volunteer study is built to answer one question: does AH-008 clear a tolerability bar across ascending intravenous doses without triggering cardiac, laboratory, vital-sign, or infusion-related signals. That is hypothesis-generating for AH-008's future development, not a decision on clinical benefit, since no patients with disease are enrolled and no efficacy measure is registered. NCT07697560Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy SubjectsNCT07697560
Sponsor and pipeline context
AnHorn Medicines Co. Ltd. is the study's industry sponsor, and this is the company's second clinical-stage trial across its portfolio, alongside one completed study. No prior AH-008 trials have been terminated, and the asset has one other trial on record, the subject study itself. AH-008's target and mechanism are not established in the data reviewed, and no competitor trial sharing the same target or mechanism class was identified, so the program cannot yet be placed against a specific competitive field.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.